| Literature DB >> 26977856 |
Robert S Kerrison1, Lesley M McGregor1, Sarah Marshall2, John Isitt3, Nicholas Counsell1, Jane Wardle1, Christian von Wagner1.
Abstract
BACKGROUND: In March 2013, NHS England extended its national Bowel Cancer Screening Programme to include 'one-off' Flexible Sigmoidoscopy screening (NHS Bowel Scope Screening, BSS) for men and women aged 55. With less than one in two people currently taking up the screening test offer, there is a strong public health mandate to develop system-friendly interventions to increase uptake while the programme is rolling out. This study aimed to assess the feasibility of sending a reminder to previous BSS non-responders, 12 months after the initial invitation, with consideration for its potential impact on uptake.Entities:
Mesh:
Year: 2016 PMID: 26977856 PMCID: PMC4984863 DOI: 10.1038/bjc.2016.43
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1BSS invitation flowchart with self-referral reminder added.
Characteristics of the reminder leaflet
| Easy to read | The Flesch formula was used to assess the readability of the leaflet, which gave it a score of 68.7 (equivalent of a 13–15-year reading age). Pilot participants indicated that the leaflet was ‘the right length', not ‘too positive' and ‘included enough information to make a decision about screening'. |
| General Practitioner cancer lead endorsement | The BSS programme was endorsed by the local general practitioner cancer lead for Hillingdon. A photograph and quote of the GP were included: ‘I would urge anyone aged 55–59 to take this quick, potentially lifesaving, one-off test that significantly reduces your risk of getting bowel cancer'. |
| Provincial social norms message | The leaflet included a descriptive provincial social norms message: ‘About 270 people take up the Bowel Scope Screening test at St. Mark's Hospital every month'. |
| Effective communication of risk | The antecedents and consequences of bowel cancer were used to communicate risk and explain the preventative mechanisms of bowel scope screening: ‘Bowel cancer develops from polyps, which are small growths in your bowel. Most polyps are harmless, but some can turn into cancer if left untreated. By removing any polyps in your bowel during the test, bowel scope screening is a very effective way of reducing the chance that you will get bowel cancer in the future'. |
| Patient narratives | The leaflet included two patient narratives (one male, one female). Narratives have been associated with a reduction in the perceived impact of barriers and increased perceived risk of CRC ( |
| Reducing worry about pain, discomfort and embarrassment associated with the procedure | The leaflet was designed to reduce worry about pain, discomfort and embarrassment associated with the procedure. Statements addressing pain were based on patient reported outcomes from the UK FS pilot study: ‘The test is done in private and nearly everyone says it's not embarrassing' ‘Most people say they felt no pain, or only mild pain' ( |
| Map and local transport options | The leaflet was designed to address practical barriers to screening. A map of the area, and description of local transport links to the hospital was included to help patients plan their journey. |
| Instructions on how to make an appointment | Instructions on how to make an appointment by telephone referral were reiterated in the leaflet. Patients were also informed they could call the St. Mark's Freephone telephone number for further information about the test. |
Figure 2Basic design of the study.
Sample characteristics of the reminder population
| Male | 68 | 43.9 |
| Female | 87 | 56.1 |
| Brent | 76 | 49.0 |
| Harrow | 79 | 51.0 |
| Tertile 1 (least deprived) | 31 | 20 |
| Tertile 2 | 62 | 40 |
| Tertile 3 (most deprived) | 62 | 40 |
Uptake following the reminders by gender, tertiles of the Index of Multiple Deprivation and location in the eligible sample (n=155)
| Overall ( | 24 (15.5) | — | — |
| Male ( | 6 (8.8) | — | — |
| Female ( | 18 (20.7) | 2.73 (1.02–7.35) | 0.05 |
| Harrow ( | 12 (15.2) | — | — |
| Brent ( | 12 (15.8) | 1.10 (0.35–3.40) | 0.87 |
| 1 ( | 4 (12.5) | — | — |
| 2 ( | 11 (17.2) | 1.46 (0.39–5.51) | 0.57 |
| 3 ( | 9 (14.3) | 1.08 (0.22–5.37) | 0.93 |